NAHB: A Promising Drug Target for Diseases (P40622)

Target Name: beta-Hexosaminidase Complex

NCBI ID: P40622

beta-Hexosaminidase Complex

Other Name(s): N-Acetyl-beta-hexosaminidase | beta-Acetylaminodeoxyhexosidase | Beta-Hexosaminidase | N-Acetyl-beta-D-hexosaminidase | beta-N-Acetyl-D-hexosaminidase

NAHB: A Promising Drug Target for Diseases

Beta-hexosaminidase complex (N-acetyl-beta-hexosaminidase, NABH) is a protein that is expressed in various tissues and cell types in the human body. It is a key enzyme in the glycosylation process, which is the final step in the production of many proteins. NABH is involved in the modification of the N-acetyl groups on the chains of proteins, and its activity has been linked to a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, NABH has emerged as a promising drug target and biomarker for a variety of diseases.

The NABH gene is located on chromosome 12q22 and has been studied extensively in the context of many diseases. It is a member of the hexosaminidase family, which includes a group of enzymes that are involved in the modification of the N-acetyl groups on the chains of proteins. The hexosaminidase family includes four subfamilies, including the N-acetyl-beta-hexosaminidase subfamily.

The NABH enzyme is involved in the first step of the glycosylation process, which is the N-acetylation of specific amino acids. This modification is important for the stability and functions of many proteins, and NABH is involved in the production of a variety of proteins , including collagen, heparin, and keratin, etc.

The NABH enzyme has been linked to a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, NABH has been shown to be overexpressed in a variety of cancer tissues and to contribute to tumor progression. In addition, NABH has been shown to be overexpressed in a variety of cancer tissues and to contribute to tumor progression. has been linked to the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

As a result of these connections, NABH has emerged as a promising drug target and biomarker for a variety of diseases. One approach to targeting NABH is to use small molecules that can modulate the activity of the enzyme. These small molecules can be designed to specifically interact with NABH and modulate its activity to treat diseases associated with NABH overactivity.

Another approach to targeting NABH is to use antibodies that recognize and selectively bind to the NABH enzyme. These antibodies can be used to diagnose and monitor the activity of NABH in diseases associated with NABH overactivity.

In addition to its potential as a drug target and biomarker, NABH is also a potential target for other therapies. For example, NABH has been shown to be involved in the production of extracellular matrix (ECM) proteins, which are involved in the structure and function of tissues and organs. Therefore, drugs that can modulate the activity of NABH may be useful for treating diseases associated with changes in ECM structure and function, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Conclusion

Beta-hexosaminidase complex (N-acetyl-beta-hexosaminidase, NABH) is a protein that is involved in the modification of the N-acetyl groups on the chains of proteins. Its activity has been linked to a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, NABH has emerged as a promising drug target and biomarker for a variety of diseases. The development of small molecules and antibodies that can modulate the activity of NABH may provide new treatments for these diseases.

Protein Name: Beta-Hexosaminidase Complex

The "beta-Hexosaminidase Complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about beta-Hexosaminidase Complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets